Lisata Therapeutics, based in Basking Ridge, New Jersey, focuses on developing therapies for advanced solid tumors, with its lead candidate LSTA1 enhancing anti-cancer drug penetration in tumors. The company also explores CD34+ cell therapy for various diseases, including critical limb ischemia and diabetic kidney disease.
LSTA has been in the news recently: MBX Biosciences has a cash reserve of $55 million with a 15-month operational runway, despite a 57% increase in cash burn to $44 million last year. Additionally, Senhwa Biosciences received rare pediatric disease designation from the FDA for its drug Silmitasertib, aimed at treating neuroblastoma, which affects 700-800 new patients annually in the U.S.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
